Cash and cash equivalents (USD, thousands)

Grant receivable (USD, thousands)

Prepaid expenses and other current assets (USD, thousands)

Total current assets (USD, thousands)

Restricted cash (USD, thousands)

Property and equipment, net (USD, thousands)

Right of use assets - operating leases (USD, thousands)

Right of use assets - finance leases (USD, thousands)

Intangible assets, net (USD, thousands)

Other long-term prepaid assets (USD, thousands)

TOTAL ASSETS (USD, thousands)

Accounts payable (USD, thousands)

Accrued expenses (USD, thousands)

Loans due to Juvenescence, net of debt issuance costs (USD, thousands)

Current portion of operating lease liabilities (USD, thousands)

Current portion of finance lease liabilities (USD, thousands)

Other current liabilities (USD, thousands)

Total current liabilities (USD, thousands)

Warrant liability (USD, thousands)

Loans due to Juvenescence, net of current portion (USD, thousands)

Convertible promissory notes, at fair value (USD, thousands)

Operating lease liabilities, net of current portion (USD, thousands)

Finance lease liabilities, net of current portion (USD, thousands)

TOTAL LIABILITIES (USD, thousands)

Redeemable convertible preferred stock (USD, thousands)

Preferred stock, $ 0.0001 par value, 5,000 shares authorized; none issued and outstanding (USD, thousands)

Common stock, $ 0.0001 par value, 40,000 shares authorized (USD, thousands)

Additional paid-in capital (USD, thousands)

Accumulated deficit (USD, thousands)

Total Serina Therapeutics, Inc. stockholders’ equity (deficit) (USD, thousands)

Noncontrolling interest (USD, thousands)

Total stockholders’ equity (deficit) (USD, thousands)

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) (USD, thousands)

c74d9d5bfa1574cd73ae832bff606471262b135bc0d4575567019c295cb61e16

Grant revenues (USD, thousands)

Total revenues (USD, thousands)

Research and development (USD, thousands)

General and administrative (USD, thousands)

Total operating expenses (USD, thousands)

Loss from operations (USD, thousands)

Interest expense, net (USD, thousands)

Total other income (expense), net (USD, thousands)

NET INCOME (LOSS) (USD, thousands)

Net loss attributable to noncontrolling interest (USD, thousands)

NET (LOSS) INCOME ATTRIBUTABLE TO SERINA THERAPEUTICS, INC. (USD, thousands)

NET EARNINGS (LOSS) PER COMMON SHARE: BASIC (USD)

NET EARNINGS (LOSS) PER COMMON SHARE: DILUTED (USD)

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC (thousands)

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: DILUTED (thousands)

3343ed9a292a0580064586572881b3a43b8ce90717a3abc5c6e5d1ff2d6f8491

Net Income (Loss) [USD, thousands]

Net Income (Loss) Attributable to Serina [USD, thousands]

Net Income (Loss) Attributable to Noncontrolling Interest [USD, thousands]

Depreciation and Amortization [USD, thousands]

Non-cash Lease Expense [USD, thousands]

Non-cash Interest Expense on Convertible Promissory Note [USD, thousands]

Amortization of Debt Issuance Costs [USD, thousands]

Stock-based Compensation [USD, thousands]

Change in Fair Value of Convertible Promissory Notes [USD, thousands]

Change in Fair Value of Warrants [USD, thousands]

Changes in Operating Assets and Liabilities: Grant Receivable [USD, thousands]

Changes in Operating Assets and Liabilities: Prepaid Expenses and Other Current Assets [USD, thousands]

Changes in Operating Assets and Liabilities: Accounts Payable [USD, thousands]

Changes in Operating Assets and Liabilities: Accrued Expenses [USD, thousands]

Changes in Operating Assets and Liabilities: Accounts Payable and Accrued Liabilities [USD, thousands]

Changes in Operating Assets and Liabilities: Accrued Interest on Convertible Promissory Notes [USD, thousands]

Changes in Operating Assets and Liabilities: Operating Lease Liabilities [USD, thousands]

Changes in Operating Assets and Liabilities: Related Party Payables [USD, thousands]

Changes in Operating Assets and Liabilities: Other Current Liabilities [USD, thousands]

Net Cash Used in Operating Activities [USD, thousands]

Investing Activities: Purchase of Equipment [USD, thousands]

Investing Activities: Purchase of Property and Equipment [USD, thousands]

Financing Activities: Proceeds from the Issuance of Common Stock and Warrants to Juvenescence [USD, thousands]

Financing Activities: Drawdown on Loan Facilities from Juvenescence [USD, thousands]

Financing Activities: Cash and Restricted Cash Acquired in Connection with the Merger [USD, thousands]

Financing Activities: Proceeds from the Exercise of Stock Options [USD, thousands]

Financing Activities: Proceeds from the Exercise of Post-Merger Warrants by Juvenescence [USD, thousands]

Financing Activities: Proceeds from Juvenescence Stock Purchase, Net of Issuance Costs [USD, thousands]

Financing Activities: Principal Repayment on Loan Facilities to Juvenescence [USD, thousands]

Financing Activities: Principal Repayments on Finance Lease Liabilities [USD, thousands]

Net Cash Provided by Financing Activities [USD, thousands]

Net Change in Cash and Cash Equivalents [USD, thousands]

Net Change in Cash, Cash Equivalents and Restricted Cash [USD, thousands]

Supplemental Disclosures: Cash Paid for Interest [USD, thousands]

Supplemental Non-Cash Activities: Right of Use Asset Acquired in Exchange for Operating Lease Liabilities [USD, thousands]

Supplemental Non-Cash Activities: Issuance of Common Stock Upon Conversion of Preferred Stock [USD, thousands]

Supplemental Non-Cash Activities: Issuance of Common Stock Upon Conversion of AgeX-Serina Note [USD, thousands]

Supplemental Non-Cash Activities: Merger and Issuance of Common Stock Upon Consummation of Merger on March 26, 2024 [USD, thousands]

Supplemental Non-Cash Activities: Deemed Dividend from Issuance of Warrants [USD, thousands]

Supplemental Non-Cash Activities: Derecognition of Post Merger and Incentive Warrants Liability Upon Exchange Transaction [USD, thousands]

Supplemental Non-Cash Activities: Issuance of Common Stock Warrants Upon Exchange Transaction [USD, thousands]

Supplemental Non-Cash Activities: Issuance of Warrants Upon Exercise of Post-Merger Warrants [USD, thousands]

Supplemental Non-Cash Activities: Extinguishment of Debt Upon Sale of Subsidiary [USD, thousands]

Cash and Cash Equivalents: At Beginning of the Period [USD, thousands]

Cash and Cash Equivalents: At End of the Period [USD, thousands]

Cash, Cash Equivalents and Restricted Cash: At Beginning of the Period [USD, thousands]

Cash, Cash Equivalents and Restricted Cash: At End of the Period [USD, thousands]

Serina Therapeutics (SER)

Financials